ClinConnect ClinConnect Logo
Search / Trial NCT04681781

SLC13A5 Deficiency Natural History Study - Remote Only

Launched by TESS RESEARCH FOUNDATION · Dec 18, 2020

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Epilepsy Rare Disease Movement Disorders Genetic Disorder Citrate Transporter Disorder Slc13 A5 Deficiency Eiee25 Neonatal Seizures Autosomal Recessive

ClinConnect Summary

This is a longitudinal observational study for the natural history of SLC13A5 deficiency for up to 2 years. This study does not involve any therapeutic intervention. The study includes remote visits which will be done via telephone or remote video conferencing. Translators will be available during these remote visits for non-english speaking caregivers. The initial visit will consist of collecting a detailed medical history and medical records. Prior brain imaging and available EEGs will be collected and reviewed by the study neurologist. Neuropsychological assessments will be made using Vi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Parent(s)/legal representative and/or patient must be willing and able to give informed consent/assent for participation in the study.
  • 2. Males and females of any age are eligible for this study
  • 3. Suspected or confirmed diagnosis of SLC13A5 deficiency with genetic variants in both SLC13A5 alleles and consistent clinical characteristics. Variants of uncertain significance in one or both alleles are acceptable if deemed good candidates by participant's primary geneticist or neurologist and study personnel.
  • 4. Participant and caregiver must be willing to provide clinical data and participate in standardized assessments.
  • Exclusion Criteria:
  • 1. The presence of a second, confirmed disorder, genetic or otherwise, affecting neurodevelopment or with other overlapping symptoms of SLC13A5 deficiency.
  • -

About Tess Research Foundation

Tess Research Foundation is a dedicated clinical trial sponsor committed to advancing medical research and improving treatment options for individuals affected by rare and complex disorders. Through collaboration with leading researchers, healthcare professionals, and industry partners, the foundation focuses on innovative therapeutic solutions and robust clinical trial designs. With a mission to enhance patient outcomes and quality of life, Tess Research Foundation prioritizes transparency, ethical practices, and patient-centered approaches in all its initiatives, striving to transform the landscape of healthcare through scientific discovery and advocacy.

Locations

Palo Alto, California, United States

Patients applied

0 patients applied

Trial Officials

Brenda E Porter, MD, PhD

Principal Investigator

Stanford University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials